以雷诺现象为首发表现的系统性硬化症临床特征及其相关因素

doi:10.19723/j.issn.1671-167X.2022.06.028

Abstract

CLC Number:

R593.25

靓罗,青猛蔡,香君刘,泽霖贠,春李,晓盈张. [J].Journal of Peking University (Health Sciences), 2022, 54(6): 1224-1228.

Figures/Tables 4

Table 1

Table 2

Table 3

Table 4

References 28

1	Wigley FM , Flavahan NA . Raynaud's phenomenon[J]. N Engl J Med, 2016, 375 (6): 556- 565. doi: 10.1056/NEJMra1507638
2	Pauling JD , Hughes M , Pope JE . Raynaud's phenomenon: An update on diagnosis, classification and management[J]. Clin Rheumatol, 2019, 38 (12): 3317- 3330. doi: 10.1007/s10067-019-04745-5
3	刘晶, 史群, 徐东, 等. 雷诺现象为首发表现的自身免疫性疾病疾病谱及临床特点[J]. 中华临床免疫和变态反应杂志, 2013, 7 (4): 346- 350.
4	Schneeberger D , Tyndall A , Kay J , et al. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: A multicentre study in the prospective EULAR scleroderma trials and research (EUSTAR) database[J]. Rheumatology (Oxford), 2013, 52 (3): 560- 567. doi: 10.1093/rheumatology/kes315
5	Walker UA , Tyndall A , Czirják L , et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database[J]. Ann Rheum Dis, 2007, 66 (6): 754- 763. doi: 10.1136/ard.2006.062901
6	Matucci-Cerinic M , Kahaleh B , Wigley FM . Review: Evidence that systemic sclerosis is a vascular disease[J]. Arthritis Rheum, 2013, 65 (8): 1953- 1962. doi: 10.1002/art.37988
7	Bairkdar M , Rossides M , Westerlind H , et al. Incidence and prevalence of systemic sclerosis globally: A comprehensive syste-matic review and meta-analysis[J]. Rheumatology (Oxford), 2021, 60 (7): 3121- 3133. doi: 10.1093/rheumatology/keab190
8	Galetti I , Nunzio SD , Brogelli L , et al. How do systemic sclerosis manifestations influence patients' lives? Results from a survey on patients and caregivers[J]. Curr Med Res Opin, 2021, 37 (Suppl 2): 5- 15.
9	Elhai M , Meune C , Boubaya M , et al. Mapping and predicting mortality from systemic sclerosis[J]. Ann Rheum Dis, 2017, 76 (11): 1897- 1905. doi: 10.1136/annrheumdis-2017-211448
10	Preliminary criteria for the classification of systemic sclerosis (scleroderma) . Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee[J]. Arthritis Rheum, 1980, 23 (5): 581- 590. doi: 10.1002/art.1780230510
11	van den Hoogen F , Khanna D , Fransen J , et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative[J]. Ann Rheum Dis, 2013, 72 (11): 1747- 1755. doi: 10.1136/annrheumdis-2013-204424
12	Bussone G , Mouthon L . Interstitial lung disease in systemic sclerosis[J]. Autoimmun Rev, 2011, 10 (5): 248- 255. doi: 10.1016/j.autrev.2010.09.012
13	Simonneau G , Robbins IM , Beghetti M , et al. Updated clinical classification of pulmonary hypertension[J]. J Am Coll Cardiol, 2009, 54 (Suppl 1): S43- S54.
14	Bruni C , De Luca G , Lazzaroni MG , et al. Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review[J]. Eur J Intern Med, 2020, 78, 17- 25. doi: 10.1016/j.ejim.2020.05.042
15	Denton CP , Khanna D . Systemic sclerosis[J]. Lancet, 2017, 390 (10103): 1685- 1699. doi: 10.1016/S0140-6736(17)30933-9
16	Maciejewska M , Sikora M , Maciejewski C , et al. Raynaud's phenomenon with focus on systemic sclerosis[J]. J Clin Med, 2022, 11 (9): 2490. doi: 10.3390/jcm11092490
17	Rubio-Rivas M , Corbella X , Pestaóa-Fernández M , et al. First clinical symptom as a prognostic factor in systemic sclerosis: Results of a retrospective nationwide cohort study[J]. Clin Rheumatol, 2018, 37 (4): 999- 1009. doi: 10.1007/s10067-017-3936-7
18	Launay D , Sitbon O , Hachulla E , et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era[J]. Ann Rheum Dis, 2013, 72 (12): 1940- 1946. doi: 10.1136/annrheumdis-2012-202489
19	Nihtyanova SI , Schreiber BE , Ong VH , et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis[J]. Arthritis Rheumatol, 2014, 66 (6): 1625- 1635. doi: 10.1002/art.38390
20	Wise RA , Wigley F , Newball HH , et al. The effect of cold exposure on diffusing capacity in patients with Raynaud's phenomenon[J]. Chest, 1982, 81 (6): 695- 698. doi: 10.1378/chest.81.6.695
21	Wangkaew S , Pota P , Prasertwittayakij N , et al. Incidence, predictors, and survival of pulmonary hypertension determined by echocardiography in Thai patients with early systemic sclerosis (SSc): Inception cohort study[J]. Clin Rheumatol, 2021, 40 (3): 973- 980. doi: 10.1007/s10067-020-05296-w
22	Perelas A , Silver RM , Arrossi AV , et al. Systemic sclerosis-associated interstitial lung disease[J]. Lancet Respir Med, 2020, 8 (3): 304- 320. doi: 10.1016/S2213-2600(19)30480-1
23	Khanna D , Nagaraja V , Tseng CH , et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials[J]. Arthritis Res Ther, 2015, 17, 372. doi: 10.1186/s13075-015-0872-2
24	Rubio-Rivas M , Royo C , Simeón CP , et al. Mortality and survival in systemic sclerosis: Systematic review and meta-analysis[J]. Semin Arthritis Rheum, 2014, 44 (2): 208- 219. doi: 10.1016/j.semarthrit.2014.05.010
25	Meunier P , Dequidt L , Barnetche T , et al. Increased risk of mortality in systemic sclerosis-associated digital ulcers: A systematic review and meta-analysis[J]. J Eur Acad Dermatol Venereol, 2019, 33 (2): 405- 409. doi: 10.1111/jdv.15114
26	Bering J , Griffing WL , Crowell M , et al. Progression of gastrointestinal symptoms over time in patients with systemic sclerosis[J]. Rheumatol Int, 2021, 41 (7): 1281- 1287. doi: 10.1007/s00296-021-04806-6
27	Steelandt A , Benmostefa N , Avouac J , et al. Ethnic influence on the phenotype of French patients with systemic sclerosis[J]. Joint Bone Spine, 2021, 88 (2): 105081. doi: 10.1016/j.jbspin.2020.09.013
28	Kowal-Bielecka O , Fransen J , Avouac J , et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017, 76 (8): 1327- 1339. doi: 10.1136/annrheumdis-2016-209909

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[2]	. [J]. Journal of Peking University(Health Sciences), 2001, 33(2): 181 -182 .
[3]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(6): 663 -665 .
[4]	. [J]. Journal of Peking University(Health Sciences), 2008, 40(1): 39 -42 .
[5]	. [J]. Journal of Peking University(Health Sciences), 2010, 42(6): 739 -745 .
[6]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(5): 507 -510 .
[7]	. [J]. Journal of Peking University(Health Sciences), 2000, 32(4): 300 .
[8]	. [J]. Journal of Peking University(Health Sciences), 2008, 40(2): 146 -150 .
[9]	. [J]. Journal of Peking University(Health Sciences), 2008, 40(4): 369 -373 .
[10]	. [J]. Journal of Peking University(Health Sciences), 2010, 42(2): 126 -130 .

Variables	RP onset group (n=196)	NRP onset group (n=105)	Z/t/χ²	P
Female, n (%)	169 (86.2)	88 (83.8)	0.319	0.572
Age at onset/years, $\bar x \pm s$	42.4±15.5	46.1±14.6	-2.064	0.040
Duration/months, M (P₂₅, P₇₅)	78.0 (29.0, 176.5)	52.0 (21.5, 124.5)	-1.792	0.073
Smoking, n (%)	29 (14.8)	23 (21.9)	2.418	0.120
SLE, n (%)	15 (7.7)	4 (3.8)	1.708	0.191
RA, n (%)	16 (8.2)	6 (5.7)	0.605	0.437
Inflammatory myopathy, n (%)	6 (3.1)	3 (2.9)	0.000	>0.999
Hypertension, n (%)	44 (22.4)	26 (24.8)	0.205	0.651
Diabetes, n (%)	8 (4.1)	10 (9.5)	3.602	0.058
Hyperlipidemia, n (%)	16 (8.2)	9 (8.6)	0.015	0.903

Variables	RP onset group (n=196)	NRP onset group (n=105)	χ²	P
Skin manifestations
Skin hardening/thickening	174 (88.8)	99 (94.3)	2.461	0.117
Loss of digital pad tissue	26 (13.3)	5 (4.8)	5.351	0.021
Bones/muscles manifestations
Muscle pain	34 (17.3)	20 (19.0)	0.134	0.714
Joint swelling	59 (30.1)	34 (32.4)	0.166	0.683
Arthralgia	93 (47.4)	57 (54.3)	1.278	0.258
Vascular manifestations
vFingertip ulcers	49 (25.0)	15 (14.3)	4.688	0.030
Digital gangrene	7 (3.6)	0	N/A	0.101
Cardiopulmonary system manifestations
Palpitations	22 (11.2)	14 (13.3)	0.289	0.591
ILD	92 (46.9)	32 (30.5)	7.649	0.006
PAH	39 (19.9)	10 (9.5)	5.399	0.020
Digestive involvement
Reflux/Heartburn	87 (44.4)	40 (38.1)	1.110	0.292
Stomach fullness	26 (13.3)	6 (5.7)	4.103	0.043
Intermittent abdominal pain	13 (6.6)	3 (2.9)	1.936	0.164
Renal involvement
Proteinuria	14 (7.1)	7 (6.7)	0.024	0.877
Microscopic hematuria	4 (2.0)	3 (2.9)	0.002	0.963
Renal crisis	3 (1.5)	1 (1.0)	0.000	>0.999

Variables	RP onset group (n=196)	NRP onset group (n=105)	Z/t/χ²	P
TC/(mmol/L), M (P₂₅, P₇₅)	4.35 (3.55, 5.13)	4.40 (3.70, 5.13)	-1.016	0.310
TG/(mmol/L), M (P₂₅, P₇₅)	1.55 (1.07, 2.15)	1.44 (1.04, 2.19)	-0.349	0.727
HDL-C/(mmol/L), $\bar x \pm s$	1.13 ± 0.36	1.13 ± 0.31	-0.062	0.951
LDL-C/(mmol/L), $\bar x \pm s$	2.54 ± 0.80	2.74 ± 0.75	-2.205	0.028
ALT/(U/L), M (P₂₅, P₇₅)	16.0 (11.0, 23.0)	15.0 (11.0, 21.5)	-0.764	0.445
AST/(U/L), M (P₂₅, P₇₅)	22.0 (17.0, 26.0)	20.0 (15.0, 25.0)	-1.180	0.238
Scr/(μmol/L), M (P₂₅, P₇₅)	61.5 (49.0, 69.8)	59.0 (53.0, 70.0)	-0.038	0.970
ESR/(mm/h), M (P₂₅, P₇₅)	16.0 (8.0, 25.8)	15.0 (8.0, 23.0)	-1.141	0.254
CRP/(mg/L), M (P₂₅, P₇₅)	3.1 (1.2, 7.3)	3.2 (1.5, 7.3)	-0.275	0.784
ANA positive, n (%)	190 (96.9)	97 (92.4)	2.257	0.133
Anti-Scl-70 positive, n (%)	65 (33.2)	23 (21.9)	4.189	0.041
Anti-RNP positive, n (%)	30 (15.3)	16 (15.2)	0.000	0.988
Low C3, n (%)	45 (23.0)	22 (21.0)	0.159	0.690
Low C4, n (%)	41 (20.9)	23 (21.9)	0.040	0.842
IgA elevated, n (%)	54 (27.6)	22 (21.0)	1.577	0.209
IgG elevated, n (%)	38 (19.4)	26 (24.8)	1.180	0.277
IgM elevated, n (%)	38 (19.4)	16 (15.2)	0.800	0.371

Variables	Univariate				Multivariate
Variables	B	Wald	P	OR (95%CI)	B	Wald	P	OR (95%CI)
Age at onset	-0.016	4.024	0.045	0.984 (0.968-1.000)
Diabetes	-0.906	3.406	0.065	0.040 (0.154-1.158)
Loss of digital pad tissue	1.118	4.915	0.027	3.059 (1.138-8.219)	1.290	6.103	0.013	3.634 (1.306-10.118)
Fingertip ulcers	0.693	4.576	0.032	2.000 (1.060-3.774)
ILD	0.702	7.534	0.006	2.018 (1.222-3.332)	0.679	6.688	0.010	1.972 (1.179-3.299)
PAH	0.859	5.172	0.023	2.360 (1.126-4.946)
Stomach fullness	0.926	3.875	0.049	2.524 (1.004-6.343)
Anti-Scl-70 positive	0.570	4.135	0.042	1.769 (1.021-3.066)	0.596	4.211	0.040	1.814 (1.027-3.205)
Low LDL-C	-0.330	4.548	0.033	0.719 (0.531-0.974)	-0.403	5.979	0.014	0.668 (0.484-0.923)

RICH HTML

PDF (PC)

Abstract

Cite this article

share this article

Figures/Tables 4

References 28

Related Articles 4

Metrics

Comments

Recommended 10

[1]	MA Xiang-bo,ZHANG Xue-wu,JIA Ru-lin,GAO Ying,LIU Hong-jiang,LIU Yu-fang,LI Ying-ni. Application of lymphocytes test in peripheral blood of patients with systemic sclerosis during the treatment [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 721-727.
[2]	Hong-lin ZHU,Qian DU,Wei-lin CHEN,Xiao-xia ZUO,Quan-zhen LI,Si-jia LIU. Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms [J]. Journal of Peking University(Health Sciences), 2019, 51(4): 716-722.
[3]	JI Lan-lan, WANG He, ZHANG Xiao-hui, ZHANG Zhuo-li. Correlation between nailfold capillaroscopic findings and presence of interstitial lung disease in systemic sclerosis patients [J]. Journal of Peking University(Health Sciences), 2018, 50(3): 501-506.
[4]	DOU Jing-li，BAI Li，PANG Chun-yan，ZHANG Wen-lan，ZHANG Wei，WANG Yong-fu. Therapeutic effect of adipose tissue-derived stem cells on bleomycin-induced mice of scleroderma [J]. Journal of Peking University(Health Sciences), 2016, 48(6): 970-976.